- Home
- DNLI vs TMDX Comparison
DNLI vs TMDX Comparison
Compare DNLI & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- TMDX
- Stock Information
- Founded
- DNLI 2013
- TMDX 1998
- Country
- DNLI United States
- TMDX United States
- Employees
- DNLI N/A
- TMDX N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DNLI Health Care
- TMDX Health Care
- Exchange
- DNLI Nasdaq
- TMDX Nasdaq
- Market Cap
- DNLI 2.1B
- TMDX 2.3B
- IPO Year
- DNLI 2017
- TMDX 2019
- Fundamental
- Price
- DNLI $13.89
- TMDX $123.56
- Analyst Decision
- DNLI Strong Buy
- TMDX Buy
- Analyst Count
- DNLI 15
- TMDX 10
- Target Price
- DNLI $33.85
- TMDX $127.33
- AVG Volume (30 Days)
- DNLI 1.6M
- TMDX 830.9K
- Earning Date
- DNLI 07-31-2025
- TMDX 07-30-2025
- Dividend Yield
- DNLI N/A
- TMDX N/A
- EPS Growth
- DNLI N/A
- TMDX N/A
- EPS
- DNLI N/A
- TMDX 1.41
- Revenue
- DNLI N/A
- TMDX $488,227,000.00
- Revenue This Year
- DNLI N/A
- TMDX $34.07
- Revenue Next Year
- DNLI $335.74
- TMDX $20.76
- P/E Ratio
- DNLI N/A
- TMDX $87.63
- Revenue Growth
- DNLI N/A
- TMDX 64.43
- 52 Week Low
- DNLI $10.57
- TMDX $55.00
- 52 Week High
- DNLI $33.33
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- DNLI 45.02
- TMDX 45.61
- Support Level
- DNLI $14.19
- TMDX $139.31
- Resistance Level
- DNLI $14.88
- TMDX $145.50
- Average True Range (ATR)
- DNLI 0.77
- TMDX 5.88
- MACD
- DNLI -0.03
- TMDX -2.71
- Stochastic Oscillator
- DNLI 34.55
- TMDX 12.94
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.